Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 3,726–3,750 of 27,380 studies, newest first · page 150 of 1096.

July 2025 25

  1. 2025-07-15

    A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE ε4 carriers

    ✓ Peer-reviewed Treatments Alzheimer's research & therapy

    Key finding: ApoE4 levels ascertained by the e4Quant test exhibited clear genotype-dependent stratification. +1 more finding

  2. 2025-07-15

    White matter hyperintensities contribute to early cortical thinning in addition to tau in aging

    ✓ Peer-reviewed Vascular contributions Neurobiology of Aging

    Key finding: White matter hyperintensities (WMH) are associated with cortical thinning in distant brain regions. +4 more findings

  3. 2025-07-15

    No robust add-on effects of prefrontal theta–gamma tACS to cognitive training on episodic memory in non-demented older adults

    ✓ Peer-reviewed Prevention trials Clinical Neurophysiology

    Key finding: The primary analysis demonstrated significant improvements in multiple episodic memory measures across both intervention groups, with no significant differences observed between groups. +4 more findings

  4. 2025-07-15
  5. 2025-07-15

    Ethanol consumption aggravates amyloid pathology and neuroinflammation in Alzheimer’s disease associated with inflammasome activation and ASC speck propagation

    ✓ Peer-reviewed Inflammation and the immune system Journal of Neuroinflammation

    Key finding: In this study, we show that repeated ethanol binges aggravate the amyloid pathology and plaque burden in the hippocampus of APP/PS1 mice. +4 more findings

  6. 2025-07-15

    TDP-43 proteinopathy: the complex biological and clinical findings in LATE-NC, LANS, and other mixed age-related major neurocognitive disorders

    ✓ Peer-reviewed Brain tissue and pathology Current Opinion in Psychiatry

    Key finding: Since the term limbic-predominant age-related TDP-43 encephalopathy (LATE) was coined in 2019, more than 200 articles addressing the subject were published.

  7. 2025-07-15

    Mild cognitive impairment among older adults in outpatient clinics: Awareness and knowledge needs survey

    ✓ Peer-reviewed Mild cognitive impairment Experimental Gerontology

    Key finding: The MCI symptom awareness score among older adults in outpatient clinics was 7.45 ± 3.58 points. +4 more findings

  8. 2025-07-15

    Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases

    ✓ Peer-reviewed Lewy body dementia Nature Medicine

    Key finding: Neurodegenerative diseases (NDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and frontotemporal dementia (FTD), exhibit distinct yet overlapping pathological mechanisms. +1 more finding

  9. 2025-07-15

    Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

    ✓ Peer-reviewed Risk factors JAMA Network Open

    Key finding: A total of 60 860 adults with type 2 diabetes and obesity were included, with 30 430 each in the GLP-1RA group (mean [SD] age, 57.9 [9.9] years; 50.2% female) and the other antidiabetic drug group (mean [SD] age, 58.0 [10.8] years; 51.4% female) after propensity score matching. +4 more findings

  10. 2025-07-15

    Multimodal Detection of Agitation in People With Dementia in Clinical Settings: Observational Pilot Study

    ✓ Peer-reviewed Digital health tools JMIR Aging

    Key finding: The Extra Trees model achieved up to 99% accuracy for personalized wristband data, while the multilayer perceptron model performed best in general models with 98% accuracy. +4 more findings

  11. 2025-07-15

    An explainable and efficient deep learning framework for EEG-based diagnosis of Alzheimer's disease and frontotemporal dementia

    ✓ Peer-reviewed Digital health tools Frontiers in Medicine

    Key finding: The early and accurate diagnosis of Alzheimer's Disease and Frontotemporal Dementia remains a critical challenge, particularly with traditional machine learning models which often fail to provide transparency in their predictions, reducing user confidence and treatment effectiveness. +4 more findings

  12. 2025-07-15

    Associations of cardiovascular health assessed by life’s crucial 9 with incident cardiovascular disease and dementia: A prospective cohort study

    ✓ Peer-reviewed How common it is The Journal of Prevention of Alzheimer s Disease

    Key finding: Of 289,649 included participants, 137,480 (47.5 %) were male, and the mean age was 56.6 ± 8.1 years. +4 more findings

  13. 2025-07-15

    The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia

    ✓ Peer-reviewed Getting a diagnosis Journal of the Neurological Sciences

    Key finding: The advent of highly sensitive single-molecule array (Simoa®) assays has significantly enhanced the accuracy of blood-based biomarker quantification, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181). +2 more findings

  14. 2025-07-15
  15. 2025-07-15

    APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases

    ✓ Peer-reviewed Digital health tools Nature medicine

    Key finding: Analysis of the dorsolateral prefrontal cortex proteome for 262 donors from the Accelerating Medicines Partnership for AD UPenn Proteomics Study revealed a consistent APOE ε4 phenotype, independent of neurodegenerative pathology, including amyloid-β tau and gliosis for all diseases, as well as TDP-43 in ALS and FTD cases, and α-synuclein in PD and PDD cases. +2 more findings

  16. 2025-07-15

    A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial (PENSA study)

    ✓ Peer-reviewed Treatments The journal of prevention of Alzheimer's disease

    Key finding: After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). +3 more findings

  17. 2025-07-15

    Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community

    ✓ Peer-reviewed Biomarkers Alzheimer's & Dementia

    Key finding: 363 participants across three cohorts, including familial (PSEN1 mutation) and general community cohorts +3 more findings

  18. 2025-07-14
  19. 2025-07-14

    Pathological mechanisms and treatment progression of Alzheimer’s disease

    ✓ Peer-reviewed Disease mechanisms European journal of medical research

    Key finding: Current therapeutic approaches, including recently approved anti-amyloid immunotherapies, demonstrate limited clinical efficacy and significant adverse effects, highlighting the need for alternative treatment strategies.

  20. 2025-07-13

    A combined naturalistic driving, clinical, and neurobehavioral data set for investigating aging and dementia

    ✓ Peer-reviewed Risk factors Scientific data

    Key finding: Alzheimer's disease and related dementia (ADRD) are becoming increasingly prevalent and are predicted to affect up to 153 million globally by 2050. +4 more findings

  21. 2025-07-12

    End-of-life care in hospitalized patients with dementia

    ✓ Peer-reviewed End-of-life care The Journals of Gerontology Series A

    Key finding: The study cohort comprised patients with a mean age of 87.2 ± 7.2 years (n = 100), 63% of whom had lived in nursing homes. +3 more findings

  22. 2025-07-12
  23. 2025-07-12

    Challenges and needs in dementia care: people with dementia and family caregivers’ experiences from diagnosis to follow-up in Swedish primary care: a qualitative study

    ✓ Peer-reviewed Caregiving Scandinavian Journal of Primary Health Care

    Key finding: This study explores how older people with dementia and their family caregivers experience the process from diagnosis to follow-up in primary care, what support is needed, what works well and what could be improved. +1 more finding

  24. 2025-07-12

    Cerebral small vessel disease in memory center patients with dementia with lewy bodies and Alzheimer’s disease

    ✓ Peer-reviewed Getting a diagnosis Alzheimer s Research & Therapy

    Key finding: We included 71 DLB (76.8 ± 7.4 years old, 25 females) and 71 age- and sex-matched AD patients (and 75.2 ± 5.3 years old, 27 females). +4 more findings

  25. 2025-07-11

    Emerging biomarkers and frontier therapies: unveiling the role of endothelial dysfunction in cerebral small vessel disease

    ✓ Peer-reviewed Vascular contributions Frontiers in Neurology

    Key finding: Cerebral small vessel disease (cSVD), a major contributor to stroke, cognitive decline, and vascular dementia, accounts for around 25% of ischemic strokes and significantly impacts age-related neurological disability.

Browse the library by subject, with the full score breakdown →